Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.
Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3, indicating a new release.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.3%
- Check44 days agoChange DetectedThe status of the drug has changed to 'Terminated' as the sponsor is no longer supporting it, replacing the previous status of 'Active, not recruiting'.SummaryDifference2%
- Check49 days agoChange DetectedThe website has updated its status from 'Recruiting' to 'Active, not recruiting' as of July 25, 2024.SummaryDifference1%
- Check51 days agoChange DetectedThe website has been updated to version 2.10.0, introducing new features for viewing and comparing study record versions.SummaryDifference6%
- Check59 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.3%
Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.